Eli Lilly & Co's (LLY) Verzenio Approved by FDA as First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer

Go back to Eli Lilly & Co's (LLY) Verzenio Approved by FDA as First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer

Berenberg Upgrades Eli Lilly (LLY) to Buy

October 11, 2021 6:05 AM EDT

Berenberg analyst Kerry Holford upgraded Eli Lilly (NYSE: LLY) from Hold to Buy with a price target of $270.00.

The analyst commented, "Pipeline progress has effectively locked in Eli Lillys (Lilly) long-term sales growth, which now stands at 10% pa versus a peer average... More